Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.3871
-0.0228 (-5.56%)
At close: Nov 19, 2026, 4:00 PM EST
0.4000
+0.0129 (3.33%)
After-hours: Nov 19, 2026, 7:30 PM EST
Coherus Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 53.64 | 42.17 | 26.39 | 257.24 | 211.04 | 326.55 |
| 53.64 | 42.17 | 26.39 | 257.24 | 211.04 | 326.55 | |
Revenue Growth | 44.36% | 59.81% | -89.74% | 21.89% | -35.37% | -31.37% |
Cost of Revenue | 16.19 | 13.81 | 8.73 | 158.99 | 70.08 | 57.59 |
Gross Profit | 37.45 | 28.36 | 17.66 | 98.25 | 140.96 | 268.96 |
Selling, General & Admin | 86.29 | 95.9 | 114.88 | 185.62 | 198.48 | 169.71 |
Research & Development | 96.57 | 108.89 | 91.83 | 105.84 | 199.36 | 363.11 |
Operating Expenses | 182.86 | 204.79 | 206.72 | 291.45 | 397.84 | 532.82 |
Operating Income | -145.41 | -176.43 | -189.05 | -193.2 | -256.88 | -263.86 |
Interest Expense | -9.54 | -9 | -10.73 | -40.54 | -32.47 | -22.96 |
Interest & Investment Income | 7 | 7 | 4.5 | 2.8 | 1.9 | 1.4 |
Other Non Operating Income (Expenses) | -1.59 | 0.01 | 3.12 | 2.67 | 1.92 | -1.68 |
EBT Excluding Unusual Items | -149.54 | -178.42 | -192.16 | -228.27 | -285.53 | -287.1 |
Merger & Restructuring Charges | - | - | - | -10 | - | - |
Asset Writedown | -2.6 | -4.7 | -10.6 | - | - | - |
Other Unusual Items | -3.36 | - | -12.63 | - | -6.22 | - |
Pretax Income | -155.5 | -183.12 | -215.39 | -238.27 | -291.75 | -287.1 |
Income Tax Expense | - | - | - | -0.38 | - | - |
Earnings From Continuing Operations | -155.5 | -183.12 | -215.39 | -237.89 | -291.75 | -287.1 |
Earnings From Discontinued Operations | 19.57 | 351.15 | 243.9 | - | - | - |
Net Income to Company | -135.94 | 168.02 | 28.51 | -237.89 | -291.75 | -287.1 |
Net Income | -135.94 | 168.02 | 28.51 | -237.89 | -291.75 | -287.1 |
Net Income to Common | -135.94 | 168.02 | 28.51 | -237.89 | -291.75 | -287.1 |
Net Income Growth | - | 489.41% | - | - | - | - |
Shares Outstanding (Basic) | 142 | 117 | 115 | 94 | 78 | 75 |
Shares Outstanding (Diluted) | 142 | 117 | 115 | 94 | 78 | 75 |
Shares Change | 22.26% | 2.26% | 21.65% | 21.30% | 2.89% | -9.63% |
EPS (Basic) | -0.96 | 1.43 | 0.25 | -2.53 | -3.76 | -3.81 |
EPS (Diluted) | -0.96 | 1.43 | 0.25 | -2.53 | -3.76 | -3.81 |
EPS Growth | - | 476.38% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -173.71 | -138.51 | -20.44 | -174.88 | -241.12 | -38.72 |
Free Cash Flow Per Share | -1.23 | -1.18 | -0.18 | -1.86 | -3.11 | -0.51 |
Gross Margin | 69.81% | 67.24% | 66.93% | 38.19% | 66.79% | 82.36% |
Operating Margin | -271.09% | -418.37% | -716.41% | -75.10% | -121.72% | -80.80% |
Profit Margin | -253.43% | 398.43% | 108.03% | -92.48% | -138.25% | -87.92% |
Free Cash Flow Margin | -323.85% | -328.45% | -77.46% | -67.98% | -114.25% | -11.86% |
EBITDA | -141.92 | -172.51 | -183.78 | -189.41 | -253.18 | -260.4 |
EBITDA Margin | -264.58% | - | - | -73.63% | -119.97% | -79.74% |
D&A For EBITDA | 3.49 | 3.92 | 5.28 | 3.79 | 3.7 | 3.45 |
EBIT | -145.41 | -176.43 | -189.05 | -193.2 | -256.88 | -263.86 |
EBIT Margin | -271.09% | - | - | -75.10% | -121.72% | -80.80% |
Advertising Expenses | - | 6.6 | 7.4 | 10.9 | 10.5 | - |